Gentis news

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1405
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z7475342255361_6d2a37fa1d1528705dc55057db6a4222.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 0000-00-00
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-29 13:20:52
            [updated_time] => 2026-01-30 13:30:18
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-and-Phenikaa-hospital-strengthen-professional-exchange-on-preimplantation-genetic-testing
            [title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic testing
            [description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle.
            [content] => 

Responding to the growing demand for the application of PGT solutions in assisted reproduction, Eurofins GENTIS recently collaborated with Phenikaa Hospital to organize a professional working session. The meeting focused on exchanging insights and updating advanced genetic testing solutions currently applied in reproductive medicine, including specialized technologies and services developed and implemented by Eurofins GENTIS.
Representing Eurofins GENTIS, Dr. Nguyen Quang Vinh (Laboratory Director) directly presented and reported on the professional content at the session. On the Phenikaa Hospital side, the meeting was attended by a team of physicians, specialists, and technicians in assisted reproduction, who engaged in in-depth discussions on the practical application of genetic testing in IVF treatment.

At the meeting, Dr. Vinh provided an overview of the PGT testing system currently implemented at Eurofins GENTIS, with a focus on PGT-A/SR—preimplantation genetic testing for aneuploidies and structural rearrangements. PGT-A/SR enables comprehensive analysis of all 24 chromosomes, detecting numerical and structural abnormalities, including aneuploidy, deletions, duplications, and mosaicism. The application of PGT-A/SR helps IVF clinicians select embryos with higher implantation potential, reduce the risk of early miscarriage, and increase embryo transfer success rates, particularly in advanced-age patients, those with repeated IVF failures, or a history of pregnancy loss. Data shared by Eurofins GENTIS showed that embryos with chromosomal abnormalities account for nearly half of all analyzed samples. This highlights the importance of preimplantation genetic testing, as many embryos with good morphology may still harbor underlying genetic abnormalities that can directly affect pregnancy outcomes if not screened early.
In addition to PGT-A/SR, PGT-M was another topic of particular interest to Phenikaa Hospital. This solution is designed for couples who carry genes associated with inherited diseases but wish to have healthy children free from these conditions. Eurofins GENTIS has currently implemented more than 100 PGT-M protocols for a wide range of conditions such as thalassemia, spinal muscular atrophy (SMA), hemophilia, and other rare genetic disorders, using advanced technologies including next-generation sequencing (NGS), STR, SNP analysis, and karyomapping. The integration of PGT-M with IVF helps prevent genetic diseases at the embryo stage, delivering long-term benefits for the health of future generations.
Within the framework of the session, Dr. Vinh also highlighted Eurofins GENTIS’s testing capacity and internationally standardized laboratory system, featuring the Illumina MiSeq NGS platform and specialized analysis software BlueFuse. Notably, the achievement of CAP accreditation for PGT testing serves as strong evidence of quality, reliability, and standardization across the entire genetic testing workflow at GENTIS.
Beyond introducing genetic testing services and modern laboratory infrastructure, Dr. Nguyen Quang Vinh also directly addressed professional questions from Phenikaa Hospital’s experts and physicians, helping clarify practical issues related to the application of genetic testing in assisted reproduction. Physicians at Phenikaa Hospital highly appreciated the professional insights, real-world data, and testing solutions provided by Eurofins GENTIS, considering them an important foundation for improving treatment outcomes and the quality of care for IVF patients.
The professional exchange between Eurofins GENTIS and Phenikaa Hospital not only held academic value but also opened up directions for sustainable collaboration in training, clinical consultation, and the implementation of advanced genetic testing solutions. Through close cooperation, both parties expect to contribute to improving IVF treatment effectiveness, reducing the psychological and financial burden on patients, and delivering meaningful value to the community in the journey toward fulfilling the dream of having healthy children.
            [content_more] => 
            [meta_title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic te
            [meta_description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babi
            [meta_keyword] => GENTIS,Phenikaa
            [thumbnail_alt] => 
            [post_id] => 1405
            [category_id] => 14
        )

    [1] => stdClass Object
        (
            [id] => 1404
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => rabbit_media-4214.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-01-23
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-23 10:43:46
            [updated_time] => 2026-01-30 13:27:57
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Trends-and-applications-of-AI-and-omics-data-in-genetic-testing-and-reproductive-genetic-counseling
            [title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling
            [description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and development, AI has demonstrated its pivotal role in improving treatment effectiveness and personalizing healthcare. In the field of genetics and assisted reproduction, the integration of AI, bioinformatics, and Omics data is expected to create major breakthroughs, significantly enhancing the quality of screening, diagnosis, and genetic counseling.
            [content] => 
AI and omics data – The foundation of precision medicine
 The rapid development of next-generation sequencing (NGS), mass spectrometry technologies, along with the increasing capacity for collecting and storing large-scale clinical data, has generated an enormous volume of information in medical genetics. Omics data—including genomics, transcriptomics, proteomics (proteins and post-translational modifications), metabolomics (metabolites and hormones), together with bioinformatics and AI—provide a comprehensive reflection of biological characteristics at the molecular level. However, analyzing and effectively exploiting these datasets poses a major challenge if relying solely on traditional methods.
Dr. Pham Dinh Minh (R&D Director, Eurofins GENTIS) presenting at the Symposium on Reproductive Genetics and PGT
With its machine learning capabilities and multidimensional data analysis, AI enables rapid and accurate processing of complex Omics datasets, thereby uncovering potential relationships among genetic factors, clinical data, and disease risks. In assisted reproduction, this opens up opportunities to improve embryo screening quality, predict implantation potential, and provide more scientific and personalized genetic risk counseling for couples.
Eurofins GENTIS pioneers the application of AI in reproductive genetics
 According to Dr. Pham Dinh Minh (R&D Director of Eurofins GENTIS) at the Symposium on Reproductive Genetics and PGT, in recent years Eurofins GENTIS has focused on developing information technology platforms and AI applications integrated with Omics data to support genetic screening, counseling, and management of hereditary diseases. These solutions not only provide professional support for hospitals and partners but also strengthen the connection between Eurofins GENTIS, clinicians, healthcare facilities, and patients, contributing to improved user experience and healthcare service quality.
In the field of genetic analysis, Eurofins GENTIS has been researching and developing various bioinformatics tools to support the application of AI in studying the molecular mechanisms of fertilization, embryo development, and factors affecting infertility and subfertility. These studies aim to improve the success rates of in vitro fertilization (IVF) and to personalize treatment for each patient in the future.
PGT-AI – A new approach to embryo selection
One of the greatest challenges in IVF today is how to increase pregnancy rates and the likelihood of delivering healthy babies after embryo transfer. According to Dr. Pham Dinh Minh, the embryo is the decisive factor determining the success of an IVF cycle. Selecting the best embryo not only affects implantation rates but also has long-term implications for the child’s future health.
In this context, the application of artificial intelligence in preimplantation genetic testing (PGT-AI) is considered a highly promising trend. PGT-AI goes beyond the assessment of chromosomal abnormalities in embryos and aims to select the “best embryo among good embryos” from a genetic perspective.

Eurofins GENTIS Is researching the application of AI to predict embryo transfer success


Currently, Eurofins GENTIS is conducting pilot studies on applying AI to predict the success potential of embryo transfer. By analyzing the genetic data of embryos in combination with maternal clinical factors, AI can help identify relationships between embryos and their compatibility with the uterine environment. This enables clinicians to make optimal embryo selection decisions, thereby improving implantation rates and overall IVF success.
By integrating maternal clinical data and expanding the analysis of embryonic genetic data within PGT-AI, the research team at Eurofins GENTIS is developing screening and predictive models to identify healthy embryos with high implantation potential. This is regarded as an important step toward personalized counseling and assisted reproductive treatment.
Applications of AI in NIPT and newborn screening
In addition to IVF and PGT-AI, AI is also being strongly applied by Eurofins GENTIS in the fields of prenatal and newborn screening. In non-invasive prenatal testing (NIPT), Eurofins GENTIS collaborates with the University of Engineering and Technology – Vietnam National University, Hanoi, to develop bioinformatics algorithms that expand the detection spectrum of genetic variants. As a result, the sensitivity, accuracy, and specificity of NIPT have been significantly improved, contributing to higher-quality fetal anomaly screening.
Eurofins GENTIS Is researching and applying AI and Information technology in newborn screening
For newborn screening, Eurofins GENTIS is developing AI-integrated software solutions to enhance the detection of complex metabolic disorders based on mass spectrometry data. From these datasets, algorithms are built to support rapid and accurate early prediction and diagnosis of genetic diseases related to metabolic disorders in newborns.
Notably, in the process of reporting results, Eurofins GENTIS has integrated information technology and AI to interpret testing data, helping clinicians and families more easily access disease-related information, understand risks, and determine appropriate treatment directions for infants.
The application of AI and Omics data in genetic testing and counseling is ushering in a new era for assisted reproduction and precision medicine. With ongoing research and real-world applications, Eurofins GENTIS demonstrates its pioneering role in bringing advanced technologies into reproductive healthcare services in Vietnam.
In the future, as datasets become more comprehensive and AI algorithms more refined, AI-based genetic solutions are expected to support clinicians in making more accurate decisions, optimizing treatment outcomes, creating opportunities for parenthood for many infertile couples, and contributing to sustainable improvements in population health.
            [content_more] => 
            [meta_title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling
            [meta_description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1404
            [category_id] => 14
        )

    [2] => stdClass Object
        (
            [id] => 1403
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => f28d3c7874e6fbb8a2f7.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-01-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-13 16:14:28
            [updated_time] => 2026-01-19 08:30:31
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Warning-of-fraudulent-impersonation-of-Eurofins-GENTIS-requesting-customers-to-transfer-money-for-early-delivery-of-test-results
            [title] => Warning of fraudulent impersonation of Eurofins GENTIS requesting customers to transfer money for early delivery of test results
            [description] => Dear Valued customers and partners,

            [content] => 
Recently, Eurofins GENTIS has received reports from several customers about unknown individuals calling by phone, impersonating company staff, and requesting payment of shipping fees for the delivery of test results (for NIPT tests and newborn screening tests), claiming that the results would be sent directly to the customers’ homes.

In response to this situation, Eurofins GENTIS would like to clearly affirm that the Company does not make phone calls requesting customers to transfer money via telephone or to personal accounts to pay any fees related to the delivery of test results. All service fees (if any) are publicly and transparently communicated at the time of registration and are implemented strictly in accordance with Eurofins GENTIS procedures. At the same time, we do not sell, provide, disclose, or allow the leakage of customers’ personal information in any form.
Currently, Eurofins GENTIS uses only one official customer service hotline: 1800 2010 to contact customers and notify them of test results. Any calls from other phone numbers requesting money transfers or personal information are not from Eurofins GENTIS.
In the context of rapid digital technology development, personal information may be collected from various sources and exploited for fraudulent activities, causing inconvenience and even serious impacts on customers’ rights and property. Therefore, Eurofins GENTIS kindly asks our partners and customers to remain vigilant, not to provide personal information, OTP codes, or bank account details, and not to transfer money without proper verification of the information.
Upon receiving any suspicious calls or unusual information related to test results, partners and customers are kindly requested to contact Eurofins GENTIS directly via the hotline 1800 2010 for timely verification and support.
Eurofins GENTIS sincerely thanks our valued partners and customers for their trust and companionship over the years, and kindly asks everyone to share this information with relatives and the community to help prevent unfortunate risks that may occur.
For further information, please contact:
EUROFINS GENTIS HANOI:
3rd Floor, V+ Shopping Center, 505 Minh Khai, Vinh Tuy Ward, Hanoi
EUROFINS GENTIS HO CHI MINH CITY:
8/24 Nguyen Dinh Khoi, Tan Son Nhat Ward, Ho Chi Minh City
Hotline: 1800 2010
Email: dichvu@gentis.com.vn
Sincerely,
            [content_more] => 
            [meta_title] => Warning of fraudulent impersonation of Eurofins GENTIS requesting customers to transfer money for ea
            [meta_description] => Dear Valued customers and partners,

            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1403
            [category_id] => 14
        )

    [3] => stdClass Object
        (
            [id] => 1400
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 12313.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2026-01-08
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-08 15:21:13
            [updated_time] => 2026-01-15 10:03:53
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-honored-to-participate-in-the-reproductive-genetics-PGT-conference-2026
            [title] => Eurofins GENTIS honored to participate in the reproductive genetics & PGT conference 2026
            [description] => On January 18, 2026, at New World Saigon Hotel, Ho Chi Minh City, the Ho Chi Minh City Society of Reproductive Endocrinology & Infertility (HOSREM) – one of the most reputable professional organizations in reproductive medicine in Vietnam – in collaboration with specialized partners, will organize the Reproductive Genetics & PGT Conference.
            [content] => 

For many years, HOSREM has played a pioneering role in connecting the professional community, updating advances in reproductive medicine, and improving the quality of infertility treatment in Vietnam.
This year’s conference continues to serve as a key scientific forum, bringing together leading experts, physicians, and researchers to exchange knowledge, share experiences, and introduce the latest achievements in reproductive genetics, PGT technology, and modern assisted reproduction.
Eurofins introduces its speaker at the conference
At this year’s Reproductive Genetics & PGT Conference, Eurofins GENTIS is honored to present an in-depth scientific presentation, demonstrating its strong commitment to the development of assisted reproductive medicine:
Pham Dinh Minh, PhD (R&D Director, Eurofins GENTIS): “Trends and Applications of AI and Omics Data in Genetic Testing and Counseling for Assisted Reproduction”
With extensive expertise in bioinformatics, genetic technology, and artificial intelligence, Dr. Pham Dinh Minh will present:

Development trends of AI & Omics data in modern reproductive medicine

Applications of AI & Omics in genetic testing and counseling for assisted reproduction

Personalized treatment solutions to enhance clinical effectiveness



Eurofins GENTIS – Main sponsor of the reproductive genetics & PGT conference 2026
Eurofins GENTIS is proud to accompany the Conference as the Main Sponsor, demonstrating its long-term commitment to promoting genetic research and application, and improving the quality of assisted reproductive services in Vietnam.
At the event, the Eurofins GENTIS booth promises to offer many engaging activities for distinguished delegates. It will be a hub for updating the latest testing methods and technologies in assisted reproduction, helping to enhance clinical outcomes for patients.
Visitors will also have the opportunity to engage directly with Eurofins GENTIS’ experienced experts, receive answers regarding testing procedures, and explore the latest technological innovations that Eurofins GENTIS is actively researching and developing.
In addition, the Eurofins GENTIS booth will host exciting minigame activities with many lovely appreciation gifts for conference participants.
Eurofins GENTIS respectfully invites all physicians, specialists, and guests to visit its booth at the Reproductive Genetics & PGT Conference 2026 on:
 

Sunday, January 18, 2026
New World Saigon Hotel, Ho Chi Minh City 

Let us join hands with HOSREM and Eurofins GENTIS in advancing reproductive healthcare quality and creating new opportunities for future families.
We look forward to welcoming you at the Eurofins GENTIS booth.


            [content_more] => 
            [meta_title] => Eurofins GENTIS honored to participate in the reproductive genetics & PGT conference 2026
            [meta_description] => On January 18, 2026, at New World Saigon Hotel, Ho Chi Minh City, the Ho Chi Minh City Society of Reproductive Endocrinology & Infertility (HOSREM) – one of the most reputable professional organizations in reproductive medicine in Vietnam – in collaborati
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1400
            [category_id] => 14
        )

    [4] => stdClass Object
        (
            [id] => 1399
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 28_thể_ẩn.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-12-31
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-31 14:41:49
            [updated_time] => 2026-01-15 09:59:00
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-launches-GEN28-carrier-screening-test-for-28-recessive-genetic-disorders
            [title] => Eurofins GENTIS launches GEN28 – carrier screening test for 28 recessive genetic disorders
            [description] => On the journey of parenthood, nothing is more important than ensuring a child is born healthy. In reality, many individuals who appear completely healthy may unknowingly carry recessive genetic mutations. When both partners carry the same recessive gene, the risk of having a child affected by serious genetic disorders can be as high as 25%, leading to long-term impacts on health and quality of life.
            [content] => 
Therefore, as a leading institution in the number of recessive carrier screenings, Eurofins GENTIS has researched and developed GEN28 – Screening of 28 Genetic Disease Genes, designed to identify carriers, assess hereditary risks for offspring, and provide personalized genetic counseling—helping families embark on parenthood with maximum peace of mind.

GEN28 Test – screening of 28 recessive genetic disease genes
GEN28 is a screening test for 28 common and severe recessive genetic disease genes, performed using Next Generation Sequencing (NGS) technology. The test detects individuals who carry recessive disease genes. These conditions are often difficult to treat, require long-term care, and have lifelong effects on patients’ health and quality of life. With GEN28, couples can identify genetic risks early and proactively choose safe and healthy reproductive options.

Detection Scope: 28 recessive genetic disease genes
Method: GEN28 is conducted using Next Generation Sequencing (NGS). Sequencing data are processed and analyzed using specialized bioinformatics software.
Sample Type:
- 2–3 ml of whole blood collected in EDTA tubes.
- For patients undergoing GEN28 together with NIPT testing: a single 7–10 ml sample collected in the NIPT tubes currently used at Eurofins GENTIS is sufficient; no additional EDTA tube is required.
Turnaround Time: 8–10 working days

Diseases screened by GEN28
The 28 genes are associated with 25 inherited syndromes and disorders, including:

Alpha thalassemia
Beta thalassemia
Pendred syndrome / DFNB4 non-syndromic hearing loss
G6PD deficiency
Citrin deficiency
Pompe disease
Wilson disease
Phenylketonuria
Classic galactosemia (Type I)
Galactosemia Type II deficiency
Ornithine Transcarbamylase deficiency
Smith-Lemli-Opitz syndrome
Tay-Sachs disease
Fabry disease
5-alpha-reductase deficiency
Cystic fibrosis
X-linked adrenoleukodystrophy
Metachromatic leukodystrophy
Glutaric acidemia type II
Spinal muscular atrophy with respiratory distress type 1
Niemann-Pick disease
Primary carnitine deficiency
Autosomal recessive polycystic kidney disease
Hemophilia A
Hemophilia B



Benefits of GEN28 carrier screening
The GEN28 test offers significant benefits for families. If no disease-carrying gene is detected, couples can confidently plan for pregnancy with minimal concern about genetic risks. If only one partner is a carrier, detailed genetic counseling will be provided, along with an appropriate monitoring plan to ensure a safe pregnancy. When both partners carry the same disease gene, GEN28 enables couples to proactively choose safe reproductive options and effectively prevent disease transmission to their children. For families with a history of genetic disorders, the test helps identify disease-causing genes and provides genetic counseling to minimize hereditary risks for future generations.
With GEN28 by Eurofins GENTIS, healthcare planning becomes more proactive and reassuring. The test enables early detection of recessive genetic carriers, assesses the risk of disease transmission to offspring, and supports couples in making safe and informed reproductive decisions. In addition, GEN28 is accompanied by personalized genetic counseling services, delivering accurate information and practical guidance—helping families fully understand their genetic health and prepare for a healthier future for their children.


            [content_more] => 
            [meta_title] => Eurofins GENTIS launches GEN28 – carrier screening test for 28 recessive genetic disorders
            [meta_description] => On the journey of parenthood, nothing is more important than ensuring a child is born healthy. In reality, many individuals who appear completely healthy may unknowingly carry recessive genetic mutations. When both partners carry the same recessive gene, 
            [meta_keyword] => GENTIS,GEN28
            [thumbnail_alt] => 
            [post_id] => 1399
            [category_id] => 14
        )

    [5] => stdClass Object
        (
            [id] => 1398
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 605764480_1275897227908799_5804145375518154194_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-29
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-29 08:29:14
            [updated_time] => 2026-01-15 09:52:40
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Congratulations-on-the-successful-December-prenatal-class-The-journey-to-happy-motherhood-of-Andrology-and-Fertility-hospital-of-Hanoi
            [title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andrology and Fertility hospital of Hanoi
            [description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for all expectant mothers and their families in attendance. The program was not only a simple medical knowledge-sharing session but also a journey of spreading love, understanding, and strong faith for families preparing to welcome their little angels.
            [content] => 
Prenatal class – A strong foundation for the journey of motherhood
Pregnancy and childbirth are sacred journeys, yet they are also accompanied by many worries and concerns, especially for first-time mothers or families who have experienced the long and challenging journey of infertility. Understanding this, Hanoi Andrology and Fertility Hospital, in collaboration with the Happy Home Association, organized the Prenatal Class – The Journey to Happy Motherhood with the hope of providing expectant mothers with scientific knowledge, emotional stability, and the most comprehensive preparation before their delivery day.

From early morning, the hall welcomed a large number of expectant mothers and their families, creating a warm, intimate atmosphere filled with positive energy. The enthusiastic participation of families clearly reflected the strong demand for systematic prenatal education and the trust they place in the hospital’s medical team.
Experienced doctors accompanying Parents-to-be
The program was honored to have the direct participation and sharing of experienced obstetrics and gynecology specialists from Hanoi Andrology and Fertility Hospital:
 Dr. Nguyen Thi Hong Nhung, Specialist in Obstetrics and Gynecology, and Dr. Dam Dinh Tam, Specialist in Obstetrics and Gynecology.

With solid professional expertise and years of experience accompanying thousands of childbirth cases, the doctors delivered practical, easy-to-understand, and highly relevant information. The class focused on key concerns such as physical changes during pregnancy, signs of labor, natural birth and cesarean section procedures, pain management during labor, postpartum care for both mother and baby, as well as psychological preparation for welcoming the newborn.
Beyond one-way knowledge sharing, the doctors devoted significant time to directly answering every question from expectant mothers and their families — from simple concerns about nutrition and safe exercise to deeper worries about the childbirth process — all were carefully listened to and thoroughly advised.
Providing official medical knowledge – Confidence for a safe delivery
One of the most outstanding values of the prenatal class was the provision of official medical knowledge based on professional guidelines and clinical practice. This helped expectant mothers avoid misleading and unverified information widely circulating on social media.

Through the class, mothers gained a better understanding of their own bodies, learned how to listen to changes during pregnancy, and recognized early signs that require medical attention. More importantly, with sufficient knowledge and strong psychological preparation, mothers felt much more confident and reassured when approaching childbirth — a sacred and unforgettable milestone in life.
Many participants shared that after the session, they felt more relaxed, less anxious, and more confident about the journey ahead. This is precisely the goal Hanoi Andrology and Fertility Hospital always strives for when organizing its regular prenatal classes.
A loving connection space for the whole family
Not only for expectant mothers, the prenatal class also created an opportunity for future fathers and family members to join, listen, and better understand the journey of pregnancy and childbirth. Family support is a powerful source of emotional strength, helping mothers feel more secure and happy.

The class atmosphere was open and friendly, where everyone could share their own stories, emotions, and experiences. This meaningful connection helped form a warm community where families prepared for parenthood with a proactive and positive mindset.
Eurofins GENTIS – Proud to be the accompanying sponsor
Contributing significantly to the success of the program, Eurofins GENTIS was honored to be the accompanying sponsor of the Prenatal Class – The Journey to Happy Motherhood. With the mission of providing high-quality testing solutions and healthcare services, Eurofins GENTIS continuously supports Vietnamese families in achieving safe and healthy pregnancies and childbirth.
Their companionship not only ensured a well-organized and meaningful program but also reflected a long-term commitment to maternal and child healthcare, especially during the prenatal stage — the foundation for a child’s comprehensive development in the future.
In the coming time, Eurofins GENTIS will continue accompanying the regular prenatal classes of Hanoi Andrology and Fertility Hospital, contributing to the best possible physical and emotional preparation for expectant mothers before childbirth. Because Eurofins GENTIS understands that each class is not just a knowledge-sharing session, but also a meaningful milestone that builds mothers’ confidence, strengthens family bonds, and makes the journey of parenthood gentler and happier.
The Prenatal Class – The Journey to Happy Motherhood on December 27, 2025 concluded in a warm atmosphere filled with joy and trust. The success of the program once again affirms the continuous efforts of Hanoi Andrology and Fertility Hospital in providing comprehensive care for families, along with the valuable support of partners such as Eurofins GENTIS.
We wish all expectant mothers good health, peace of mind, a fulfilling pregnancy, and a smooth, gentle delivery. May all families soon welcome their beloved babies, opening a new chapter filled with happiness and love.

            [content_more] => 
            [meta_title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andro
            [meta_description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1398
            [category_id] => 14
        )

    [6] => stdClass Object
        (
            [id] => 1397
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 299d08137c20f37eaa31.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-26
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-26 15:55:42
            [updated_time] => 2026-01-14 15:50:20
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-&-andrology-and-fertility-hospital-of-Hanoi-announce-research-on-recurrent-pregnancy-loss-The-role-of-multigene-sequencing-in-genetic-screening-and-counseling
            [title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy loss: The role of multigene sequencing in genetic screening and counseling
            [description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue No. 197 of the Journal of Medical Research.
            [content] => 

The study was conducted with the objective of investigating the spectrum of genetic variants detected by FertiScan™ (a test designed to identify genetic abnormalities associated with female infertility and recurrent pregnancy loss) in women with a history of recurrent miscarriage.
The study population consisted of 20 infertile women with a history of recurrent pregnancy loss (RPL). RPL was defined as two or more consecutive spontaneous miscarriages before 20 weeks of gestation at the Hanoi Hospital of Andrology and Infertility from May to August 2023.
The study indicates that recurrent miscarriage and repeated fetal loss are common challenges in assisted reproductive practice, affecting approximately 1–5% of women of reproductive age. In addition to uterine anatomical, endocrine, immunohematological, and infectious causes, genetic factors play an important role but are not easily detected by routine testing. The cause of miscarriage remains unknown in more than 50% of these cases.
Karyotype analysis and microarray testing are useful for identifying chromosomal numerical and structural abnormalities, but they remain limited in detecting single-gene causes related to oocyte development, meiosis, implantation, and early embryonic viability. Therefore, targeted molecular genetic approaches are receiving increasing attention.
In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss. Among these, the FertiScan™ Global Female Infertility Panel is a representative tool, covering more than 70 genes involved in key pathogenic mechanisms including premature ovarian failure and ovarian dysfunction, ovarian dysgenesis, defects in oocyte maturation, abnormal oocyte–zona pellucida–fertilization interactions, genes affecting implantation and endometrial signaling, as well as DNA repair genes associated with early embryonic lethality.
This approach not only increases the detection rate of clinically significant genetic variants but also supports personalized counseling and intervention strategies, including partner testing in autosomal recessive disorders, indications for PGT-M or PGT-SR, and prenatal genetic screening when appropriate.
In Vietnam, data on the prevalence of genetic variants in women with unexplained recurrent pregnancy loss remain limited. This gap restricts optimal prognostic counseling and personalized treatment, particularly in cases with normal karyotype results but persistent pregnancy loss.
The implementation of specialized targeted NGS panels such as FertiScan™ provides value in identifying subsets of patients carrying pathogenic or likely pathogenic variants truly associated with reproductive biological mechanisms, and in documenting variants of uncertain significance (VUS) within the Vietnamese population in order to gradually standardize variant interpretation according to the classification guidelines of the American College of Medical Genetics and Genomics (ACMG). FertiScan™ results are interpreted following ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) variant classification guidelines, including pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), and benign/likely benign. Variant classification is always considered within the specific clinical and family context to ensure individual appropriateness.
From an application perspective, FertiScan™ enhances the detection of monogenic causes in patients with recurrent pregnancy loss, particularly in cases without chromosomal abnormalities identified by karyotype or microarray. The test also supports personalized genetic counseling, including partner testing in recessive genetic conditions, recommendations for PGT-M/PGT-SR, and the development of appropriate prenatal or preconception screening plans. Furthermore, FertiScan™ demonstrates strong potential for application in genetic epidemiology research in Vietnam, contributing to the establishment of population-based variant databases, thereby improving the accuracy of variant interpretation and the quality of diagnosis, counseling, and future interventions.
These results highlight the importance of systematically integrating genetic testing into the evaluation of recurrent miscarriage and fetal loss, with multigene testing positioned within structured pre- and post-test counseling and long-term follow-up strategies.
With the mission of “Enhancing the intellectual and physical well-being of the Vietnamese people,” Eurofins GENTIS continues its collaboration with the Hanoi Hospital of Andrology and Infertility to implement high-value medical research and to further develop a comprehensive ecosystem of advanced genetic testing. Through these efforts, Eurofins GENTIS contributes to delivering modern healthcare solutions and supporting medical professionals in improving reproductive healthcare for the community.
            [content_more] => 
            [meta_title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy
            [meta_description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue N
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1397
            [category_id] => 14
        )

    [7] => stdClass Object
        (
            [id] => 1396
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 06f14a7e3e4db113e85c.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-26
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-26 08:41:18
            [updated_time] => 2026-01-14 15:41:21
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-&-Andrology-and-fertility-hospital-of-Hanoi-publish-research-findings-on-recurrent-pregnancy-loss-in-the-journal-of-medical-research
            [title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent pregnancy loss in the journal of medical research
            [description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes in women with a history of recurrent pregnancy loss (RPL).
            [content] => 
The research findings were presented in the scientific article entitled: “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” which was published in Journal of Medical Research, Issue No. 197, December 2025 — a prestigious journal featuring original research and review articles in basic medicine, clinical medicine, preventive medicine, public health, and medical sociology, aimed at advancing medical knowledge and practice.

The study was conducted on 20 infertile patients with a history of recurrent pregnancy loss at the Hanoi Hospital of Andrology and Infertility between May and August 2023. According to experts, recurrent miscarriage and fetal loss represent a major challenge in assisted reproduction, affecting approximately 1–5% of women of reproductive age.

In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, significantly expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss.
Among these tools, the FertiScan™ Global Female Infertility Panel is particularly comprehensive, covering more than 70 genes involved in key pathogenic mechanisms, including: Premature ovarian failure and ovarian dysfunction. Ovarian dysgenesis. Oocyte maturation defects. Abnormal oocyte–zona pellucida–fertilization interactions. Genes affecting implantation and endometrial signaling. DNA repair genes associated with early embryonic lethality
In this study, researchers used the FertiScan™ Global Female Infertility Panel (70 genes) based on NGS technology to simultaneously examine coding regions and splice sites of the target genes.
Among the 20 patients, 12 cases (60%) carried ≥ 1 reproduction-related genetic variant, including: 4 patients harboring pathogenic or likely pathogenic variants (P/LP). Predominantly in the heterozygous state of autosomal recessive disorders.
A substantial proportion of detected variants were classified as variants of uncertain significance (VUS). Notably, variants were identified in genes with well-established biological roles, such as CEP250, TACR3, NOBOX, ZP1, and others.
The FertiScan™ test which identifies genetic causes of infertility and rare hereditary abnormalities associated with female infertility and recurrent miscarriage, as well as evaluates male reproductive health — significantly enhances the detection of monogenic causes in patients with RPL, particularly in cases without chromosomal abnormalities detected by karyotyping or microarray analysis.
The test also supports personalized genetic counseling, including: Partner testing in autosomal recessive conditions. Indications for PGT-M (preimplantation genetic testing for monogenic diseases). PGT-SR (preimplantation genetic testing for structural chromosomal rearrangements). Development of tailored prenatal and preconception screening strategies
Beyond its clinical value, FertiScan™ demonstrates strong potential in genetic epidemiology research in Vietnam, contributing to the establishment of population-specific variant databases and thereby improving variant interpretation, diagnostic accuracy, counseling, and future clinical interventions.
Researchers concluded that multigene testing such as FertiScan™ significantly improves the detection of underlying causes in unexplained RPL cases, particularly when integrated into comprehensive pre- and post-test counseling and long-term follow-up.
Sharing insights on the study, Dr. Pham Dinh Minh, R&D Director of Eurofins GENTIS and co-author of the publication, stated:“Publishing in the Journal of Medical Research is a long journey — from idea generation, study implementation, data analysis, manuscript preparation, submission, to rigorous peer review. Beyond scientific merit, the research must demonstrate strict methodological rigor and data integrity. We spent more than three months collecting data and over two years completing the project. The publication of this work is a source of pride for our team and opens new avenues for research in infertile women with recurrent pregnancy loss, helping realize the dream of parenthood for many couples and highlighting the immense potential of genetic applications in reproductive medicine in Vietnam.”
Through systematically conducted research and publication in prestigious scientific journals, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility continue to reaffirm their joint commitment to advancing genetic research and its integration into clinical practice — contributing to improved diagnostic and treatment quality in assisted reproduction across Vietnam.
            [content_more] => 
            [meta_title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent p
            [meta_description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1396
            [category_id] => 14
        )

)